In plain terms

The claim being assessed: HIV infection is the necessary cause of AIDS.

Where the evidence stands: Θ — Very well established. It predicts outcomes accurately and there are few unexplained exceptions left.

What this mechanism does: This is the thing that sets the process off.

Strongest evidence for it: Overall Θ follows registered SC3. The convergent clinical causal case is strong and predictively consistent: documented acquisition precedes immune deterioration, suppression changes clinical trajectories, interrupted suppression worsens them, and prophylaxis prevents acquisition. Host and coinfection modifiers make infection insufficient for inevitable disease. Non-HIV ICL shows that low CD4/OI phenotypes are not HIV-specific; its existence does not erase the viral causal process established by intervention, but it blocks a broader claim that HIV is necessary for all acquired immunodeficiency.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Leading among models compared

What this review means

HIV is a well-supported causal antecedent of HIV-associated AIDS; infection does not guarantee progression, and other illnesses can cause similar immune deficiency.

Implications for health and treatment: Overall Θ follows registered SC3. The convergent clinical causal case is strong and predictively consistent: documented acquisition precedes immune deterioration, suppression changes clinical trajectories, interrupted suppression worsens them, and prophylaxis prevents acquisition. Host and coinfection modifiers make infection insufficient for inevitable disease. Non-HIV ICL shows that low CD4/OI phenotypes are not HIV-specific; its existence does not erase the viral causal process established by intervention, but it blocks a broader claim that HIV is necessary for all acquired immunodeficiency.

Limits for individual care: 63 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 63 primary reports; claims: 67; verified: 67; unverified: 0. Verification is bounded attribution. Access: 3 partial-body and 60 bounded abstract/status examinations. Literature cutoff: 2026-10-09; source examination UTC date: 2026-10-10. No complete-paper audit or blinded calibration claimed.

Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 3 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

HIV is a well-supported causal antecedent of HIV-associated AIDS; infection does not guarantee progression, and other illnesses can cause similar immune deficiency.

Deciding experiment: A stronger necessity-and-sufficiency assessment would require a prospectively specified noncircular syndrome definition and independently verified naturally acquired HIV status, host modifiers, exposure history and longitudinal outcomes. Use ethically delivered target-engaged treatment and adjudicated natural-course/clinical-care observations; do not induce infection or withhold effective therapy. The purpose is causal scope discrimination rather than recreating established treatment harm.

Belief versus evidence: Overall Θ follows registered SC3. The convergent clinical causal case is strong and predictively consistent: documented acquisition precedes immune deterioration, suppression changes clinical trajectories, interrupted suppression worsens them, and prophylaxis prevents acquisition. Host and coinfection modifiers make infection insufficient for inevitable disease. Non-HIV ICL shows that low CD4/OI phenotypes are not HIV-specific; its existence does not erase the viral causal process established by intervention, but it blocks a broader claim that HIV is necessary for all acquired immunodeficiency.

Best-supported rival: HIV with host and coinfection modifiers. The strongest causal separation is randomized virus-directed suppression with measured viral/CD4 change and independently adjudicated clinical endpoints, complemented by prevention of acquisition. Compatible modifiers are not competing denials and are not ranked as a fully proven causal bundle.

COMPETING MECHANISTIC MODELS

Rank 1: HIV-driven acquired immunodeficiency (Θ). Persistent HIV infection drives a modifiable immune-deficiency trajectory. Prospective acquisition and randomized suppression, interruption and prevention findings converge. Host controllers, residual disease and treatment timing preclude infection-alone sufficiency.

Rank 2: HIV with host and coinfection modifiers (Γ). Host factors and concurrent diseases modify a viral causal trajectory. Genetic, age and coinfection findings and timing trials explain meaningful heterogeneity. This is compatible with the nominal viral antecedent; the full set of proposed modifier mechanisms is not selectively proven.

Rank 3: Non-HIV immunodeficiency phenocopies (Β). Other conditions produce low CD4 counts and opportunistic disease. ICL cohorts document non-HIV clinical lookalikes. They do not explain HIV-linked acquisition and randomized viral-suppression effects or identify a universal alternative cause.

Rank 4: Nonviral exposure or behavioral confounding (Α). HIV measurements merely mark another exposure causing the syndrome. Exposure and historical observational cohorts alone could be confounded. Specific acquisition prevention, infant progression benefit and randomized suppression/interruption are poorly explained by confounding alone.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

HIV infection is the necessary cause of AIDS.

SC3 is the clinical causal claim at the registered scope; narrower molecular, treatment or inherited-syndrome findings cannot replace it. Primary-subclaim aggregation is fixed before grading.

Selection: remaining-priority list position 8 from the editorial list of 2026-10-09. Registered claim assessed against original sources; existing HIV draft consulted after a source-based checkpoint. This is not independent blinded calibration.

Evidence and causal interpretation

Rubric fit: 05-immunology-inflammation is the closest rubric to acquired immunodeficiency, but the causal target is a virus rather than an upstream cytokine. Its targeted-human-therapy and natural-experiment definitions are applied to viral suppression and clinical disease trajectories. This explicit scope-fit adaptation retains clinical endpoints and target alignment; inflammatory-marker changes do not cross thresholds. The universal distinction between necessity and sufficiency governs the nominal claim.

The strongest clinical evidence is intervention-sensitive, not a circular AIDS classification. START improved the clinical composite and serious AIDS-related outcomes with marked viral suppression and CD4 differences; its event-review committee was blinded. All-cause mortality alone was not significant. SMART provided a counter-direction test: episodic suppression increased opportunistic disease or death. CHER extended early-treatment benefit to infected infants. These are different disease stages and clinical cohorts, not three reprints of one trial. [51] [52] [60]

HPTN052 reduced linked acquisition and later first AIDS events. Its later primary clinical composite and mortality comparisons were not significant; the primary-composite null is retained beside the positive AIDS secondary outcome. TEMPRANO and Haiti supply further early-treatment clinical evidence. The HPTN052 transmission and clinical papers share randomization and are grouped. [58] [61] [53] [30]

Acquisition prevention is a different causal link from improving existing illness. Partners PrEP, iPrEx and maternal/infant zidovudine reduce newly diagnosed HIV infection under randomized comparisons. Clinical benefit and infection prevention still share pharmacological vulnerability, so they are complemented by prospective acquisition trajectories and cautiously interpreted host-susceptibility findings; multiple antiretroviral drugs are not automatically independent mechanistic proofs. [57] [56] [59] [1] [12]

Predictive limits matter. Early ART in tuberculous meningitis had no mortality benefit and more severe harms; active-active dose comparisons show toxicity and nonmonotonic benefit. Small interruption and host-genetic nulls do not overturn larger clinical trajectories. Non-HIV ICL causes CD4 deficiency and opportunistic disease, making those findings nonspecific. This assessment does not claim HIV is necessary for every acquired immune-deficiency phenotype. [32] [34] [35] [46] [47]

Controllers and long-term nonprogressors demonstrate heterogeneous infection courses. CASCADE nonprogression includes untreated status and CD4 at least 500, not simply being AIDS-free; its percentages must not be repeated as isolated AIDS-free survival. Infected CCR5 deletion homozygotes also disprove absolute resistance. These findings constrain sufficiency and absolute host protection while retaining HIV as an etiologic antecedent in the HIV-associated syndrome. [63] [18] [49]

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. Overall Θ follows registered SC3. The convergent clinical causal case is strong and predictively consistent: documented acquisition precedes immune deterioration, suppression changes clinical trajectories, interrupted suppression worsens them, and prophylaxis prevents acquisition. Host and coinfection modifiers make infection insufficient for inevitable disease. Non-HIV ICL shows that low CD4/OI phenotypes are not HIV-specific; its existence does not erase the viral causal process established by intervention, but it blocks a broader claim that HIV is necessary for all acquired immunodeficiency. Sensitivities: weakest-link Η; primary-subclaim Θ; scope-matched Θ.

Decisive-perturbation inventory and causal tally

[51] START immediate treatment reduced the primary clinical composite and serious AIDS events with improved CD4 trajectory and viral suppression. Open-label strategy but blinded event review; interim stopping, residual events and nonsignificant all-cause mortality are retained. It does not prove infection-alone sufficiency.

[52] SMART CD4-guided episodic ART increased opportunistic disease/death versus continuous suppression; rising RNA and falling CD4 aligned with harm. Specific interruption strategy and previously treated population; mediator adjustment is not perfect causal mediation and toxicity/coinfections still matter.

[53] TEMPRANO early ART and tuberculosis preventive treatment independently reduced severe clinical illness or death. Combined clinical composite and setting-specific coinfection prevention; ART and IPT are separate interventions, not proof that all mortality is HIV alone.

[54] Double-blind AZT versus placebo reduced deaths and opportunistic infections over short follow-up with improved function. Selected advanced disease, early termination and drug toxicity limit magnitude and long-term inference; one drug alone does not settle mechanism specificity.

[58] HPTN052 early treatment reduced linked partner acquisition and clinical events. Transmission and clinical follow-up share the same randomization as PMID24602844 and cannot be counted as separate causal lines.

[59] Randomized maternal/infant zidovudine reduced infant acquisition versus placebo. An acquisition-prevention link complements progression trials but alone does not prove downstream AIDS inevitability or drug harmlessness.

[60] CHER earlier infant ART reduced mortality and serious clinical progression with improved CD4 percentages. Infant baseline eligibility, limited early follow-up and reassessment after stopping restrict extrapolation; no infection-alone sufficiency proof.

Tally: 10 positive qualifying study units across scoped subclaims; 18 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Repeat SMART and HPTN052 reports count once per shared parent contrast. Prevention incidence and clinical progression are different causal links; no trial establishes both infection-alone sufficiency and universal AIDS inevitability. Active-active dose/prophylaxis contrasts and null comparisons are discriminators, not positive nominal crossings.

Cap audit, precedence and Β/Γ/Δ boundary

Clinical interventions cross within prespecified human infection and baseline scopes. The universal pure-association cap binds each prognostic/allele-frequency report individually, not a causal set complemented by randomized clinical perturbation. The rubric is explicitly adapted to targeted viral treatment rather than broad immunosuppression. Non-HIV phenocopies constrain phenotype specificity; they are not discarded or relabeled as HIV infection.

Universal six-cap audit: 1: No in-vitro-only inference supports the nominal clinical cause. 2: Cohort and allele correlations are individually limited; the randomized clinical set supplies complementary causal evidence. 3: No model overexpression result is transferred to humans. 4: Clinical AIDS/OI/death endpoints accompany viral/CD4 changes; biomarker-only SMART secondary findings are not positive clinical crossings. 5: No forced-transfer or seeding evidence is used. 6: Host inherited susceptibility findings stay within genotype/exposure scope and do not prove absolute protection. None is reapplied to downgrade an independently complementary same-scope causal set.

Gamma hard-rule audit: The conclusion does not rest on inflammatory markers, ex vivo findings, or correlation alone. Human targeted suppression changes clinical progression; temporality, prevention and host susceptibility provide complementary causal constraints. Specific timing nulls, treatment toxicities and rare host protection are retained; infection alone is not universally sufficient.

SC1 field-valid definition: “ - Cell-type-specific conditional knockout or depletion - Pathway-specific blockade (not broad immunosuppression) changing disease course - Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: yes. Documented seroconversion precedes immune deterioration across clinical exposure settings. This observational chain is interpreted together with randomized viral suppression and clinical rescue; it is not made causal by prognostic RNA correlations alone.

SC2 field-valid definition: “ - Cell-type-specific conditional knockout or depletion - Pathway-specific blockade (not broad immunosuppression) changing disease course - Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: yes. Earlier sustained ART improves CD4 and clinical outcomes, while interruption harms selected populations. Broad predictive consistency survives known timing and toxicity limits. Clinical suppression benefit is not infection-alone sufficiency.

SC3 field-valid definition: “ - Cell-type-specific conditional knockout or depletion - Pathway-specific blockade (not broad immunosuppression) changing disease course - Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: yes. HIV is a necessary causal antecedent of the HIV-associated AIDS process under the registered clinical distinction, supported by convergent acquisition, temporality and suppression evidence rather than classification alone. Generic immunodeficiency has other causes. Host controllers and treatment change progression without removing the viral antecedent. Necessity does not imply inevitable AIDS.

Upward threshold ladder

SC1 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: yes.

SC1 Ε: “Requires context-specific causality with explicit scope restriction.” Satisfied: yes.

SC1 Ζ: “Requires multiple convergent causal manipulations and reduced plausibility of downstream-only interpretations.” Satisfied: yes.

SC1 Η: “Requires robust upstream causal evidence across systems and interventions.” Satisfied: yes.

SC1 Θ: “Requires predictive consistency and minimal contradiction in the claimed disease scope.” Satisfied: no. Extend prospective consistency into the claimed clinical disease scope with independently validated etiologic ascertainment; existing broad inference is already supported by complementary targeted human interventions.

SC2 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: yes.

SC2 Ε: “Requires context-specific causality with explicit scope restriction.” Satisfied: yes.

SC2 Ζ: “Requires multiple convergent causal manipulations and reduced plausibility of downstream-only interpretations.” Satisfied: yes.

SC2 Η: “Requires robust upstream causal evidence across systems and interventions.” Satisfied: yes.

SC2 Θ: “Requires predictive consistency and minimal contradiction in the claimed disease scope.” Satisfied: yes.

SC2 Ω: “Requires necessity and sufficiency of the immune mechanism within the claimed scope.” Satisfied: no. Ω would require necessity and sufficiency of the precise immune mechanism under predetermined host and clinical conditions; suppression effects do not establish infection-alone sufficiency.

SC3 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: yes.

SC3 Ε: “Requires context-specific causality with explicit scope restriction.” Satisfied: yes.

SC3 Ζ: “Requires multiple convergent causal manipulations and reduced plausibility of downstream-only interpretations.” Satisfied: yes.

SC3 Η: “Requires robust upstream causal evidence across systems and interventions.” Satisfied: yes.

SC3 Θ: “Requires predictive consistency and minimal contradiction in the claimed disease scope.” Satisfied: yes.

SC3 Ω: “Requires necessity and sufficiency of the immune mechanism within the claimed scope.” Satisfied: no. Ω would require both necessity and sufficiency under a noncircular, prospectively fixed clinical phenotype and host scope. Intentionally withholding effective care or inducing infection is not an acceptable test.

Upper ladder: Orthogonal temporality, randomized suppression and prevention, and host susceptibility support the assembled clinical causal inference. Single observational limitations are not reimposed on that set. Ω remains unearned: infection is not sufficient for AIDS independently of host, duration, treatment and competing outcomes.

Independence: The lines constrain distinct errors: chronology, treatment allocation/outcome interpretation, acquisition classification, and pharmacological specificity. Prevention and suppression share drug mechanisms, and some pooled cohorts share participants; these dependencies are explicit. The clinical necessity inference rests on the assembled human set, not on four automatically independent publications. No controlled experimental infection or operational virology is required.

Prospective acquisition-to-deterioration chronology [1]: Excludes purely reverse-temporal HIV measurement after AIDS onset; does not alone exclude all exposure or host confounding.

Randomized targeted suppression and withdrawal [51, 52, 60]: Reduces treatment-selection, behavioral exposure and retrospective chronology errors; blinded START event review reduces outcome-adjudication bias. Shared viral-treatment off-target or care effects are considered explicitly.

Randomized prevention of acquisition [57, 59]: Tests incident agent acquisition rather than symptom improvement, opposing a downstream marker-only interpretation. Shares some drug classes with treatment trials and is not fully independent of pharmacological specificity.

Host susceptibility and resistance boundary [12, 18, 21]: Predetermined host variation supplies a non-drug axis, but ancestry, exposure matching and rare exceptions limit the instrument; it is complementary Moderate evidence rather than a standalone Strong necessity proof.

Falsification and pitfalls

No rubric-05 falsification pattern was triggered, so no additional downgrade is applied. The interpretive pitfalls this case does carry are surfaced in the prose above and in KNOWLEDGE GAPS: definitional circularity between HIV status and the syndrome definition, which the intervention evidence rather than the classification answers; phenotype similarity treated as etiologic identity, which non-HIV idiopathic CD4 lymphocytopenia excludes; prevention of acquisition conflated with modification of established disease; and repeated reports of one randomization (SMART, HPTN052) treated as independent causal lines. None of these alters the level.

Adversarial steelman: above, then below

Case for Ω: exposure-to-disease and prevention/suppression findings support necessity, and untreated infection frequently precedes AIDS. But a necessary antecedent is not sufficient without host, persistence, time and disease context. Controllers, effective treatment and non-HIV phenocopies require predefined scope and do not allow infection-alone sufficiency.

Case for Η: clinical strategies are open-label and pharmacological, susceptibility cohorts are confounded, and many individual biomarkers fail. Yet blinded clinical event review, infant and adult randomized benefits, an interruption counter-direction test, and acquisition prevention provide consistent complementary prediction at the claimed scope. These weaknesses limit precision and confidence without reducing the clinical antecedent to an association.

Retain Θ for the registered HIV-associated clinical causal antecedent, with High confidence: replication across independent multinational cohorts and randomized trials is extensive and well established. The bounded access of this audit limits what this document verified, not the density of the underlying evidence. Reject Ω for infection-alone sufficiency and reject a generic low-CD4 phenotype as the nominal disease definition.

Final score, causal direction and M/S/D

Overall Θ follows registered SC3. The convergent clinical causal case is strong and predictively consistent: documented acquisition precedes immune deterioration, suppression changes clinical trajectories, interrupted suppression worsens them, and prophylaxis prevents acquisition. Host and coinfection modifiers make infection insufficient for inevitable disease. Non-HIV ICL shows that low CD4/OI phenotypes are not HIV-specific; its existence does not erase the viral causal process established by intervention, but it blocks a broader claim that HIV is necessary for all acquired immunodeficiency.

Acquisition is documented before immune deterioration, so the proposed infection is not solely a disease consequence (step 1). Targeted treatment changes immune and clinical trajectories, rejecting causal irrelevance (step 2). Initiation by infection and clinical dependency on continued viral activity justify primary driver at step 3 within the HIV-associated syndrome. OI organisms and host factors remain contributing causes; primary driver does not mean sole sufficient cause.

Momentum: Mechanistic only. Clinical intervention programs such as START (NCT00867048), CHER (NCT00102960), HPTN052 (NCT00074581) and contemporary elite-controller phenotyping (PMID38376918) continue mechanistic and treatment questions, but these examined completed programs do not constitute a named ongoing experiment that could prove infection-alone sufficiency. No verified next-Ω experiment is claimed.

Stability: Stable. No specific verified pending result likely to reverse the clinical causal antecedent assessment was identified. Stable follows the framework definition and does not assert permanent completeness.

Divergence: Aligned. Field framing mapped to Θ; assessed Θ; signed gap 0, Aligned. This is an explicit interpretation of clinical author conclusions, not a claim of a measured HSEF field vote. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

A stronger necessity-and-sufficiency assessment would require a prospectively specified noncircular syndrome definition and independently verified naturally acquired HIV status, host modifiers, exposure history and longitudinal outcomes. Use ethically delivered target-engaged treatment and adjudicated natural-course/clinical-care observations; do not induce infection or withhold effective therapy. The purpose is causal scope discrimination rather than recreating established treatment harm.

Readout: Predetermined clinical immune-deficiency trajectory, verified viral engagement and independently adjudicated opportunistic events. Controls: Independent diagnostic confirmation, explicit non-HIV phenocopy comparator, blinded clinical adjudication and prespecified host/timing scope. Supporting: Prospectively correct cause-specific prediction and target-dependent trajectory alteration across the predetermined scope. Falsifying: Repeated independently verified HIV-negative cases meeting a genuinely same-cause noncircular syndrome definition, or engaged suppression without predicted causal alteration after accounting for established timing irreversibility.

KNOWLEDGE GAPS

A necessary antecedent is distinct from infection-alone sufficiency.

Specific host and coinfection mechanisms remain incompletely identified.

Which residual outcomes reflect irreversible injury, coinfection, treatment toxicity or ongoing viral biology?

Phenotype similarity cannot establish etiologic identity.

Selected body access and unexamined linked correction details limit this review.

REVIEWER NOTES

The 63 primary clinical reports have bounded original abstract/status examinations; three also have selected original clinical body passages. Most papers and supplements were not read completely. Consensus Pro browser threads supplement discovery; their verbatim documents and connector export metadata are retained. Consensus counts do not substitute for examined original reports. The resumed audit added Scite anchor tallies/outgoing contexts and SciSpace discovery; no incoming contrasting-statement audit or independent blinded grading was performed. Popularity is editorial interest, not measured public demand. HIV discussion is limited to clinical causal evidence. A mistakenly recalled PMID was verified by its unrelated title and excluded before selection.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Original START abstract shows a positive primary clinical composite for immediate ART, supporting disease modification rather than merely changing a laboratory marker. PMID 26192873.

Original SMART abstract links episodic treatment with increased opportunistic disease/death and rising viral RNA. This controlled perturbation carries stronger causal weight than correlation alone. PMID 17135583.

Original clinical follow-up abstract retains the nonsignificant primary composite (p=.074) while noting the positive AIDS-event comparison (p=.031). Secondary benefit is not substituted for a primary result. PMID 24602844.

Original CASCADE abstract defines progression-free jointly as no AIDS, ART-naive and CD4 at least 500. Those percentages are not simply the percentage remaining AIDS-free. PMID 26423816.

Original ICL follow-up shows an HIV-negative immune phenotype. The registered causal claim concerns HIV-associated AIDS, not every immune-deficiency presentation. PMID 18456875.

Consensus was used to identify literature and cross-check specific claims about study design, endpoints, scope and research gaps. Those claims were checked against original primary abstracts/status records and, for selected studies, original Methods or Results passages. Consensus output was not treated as original full text. Source-specific access depth and receipts are retained. Scite supplied one five-anchor citation-context/tally query; returned contexts were outgoing references, not an audited incoming contradiction set. SciSpace supplied one discovery pass; it added no primary-count credit.

Research timeline and gap priorities

Selected publication milestones through 9 October 2026. These dates identify source publication years, not priority claims or a comprehensive history.

1987 — Placebo-controlled AZT trial measures short-term clinical outcomes. PMID 3299089.

1994 — Maternal and infant prophylaxis tests HIV acquisition. PMID 7935654.

1996 — Plasma viral load predicts clinical prognosis observationally. PMID 8638160.

2006 — SMART suppression/withdrawal design tests clinical disease modification. PMID 17135583.

2008 — CHER early infant treatment tests mortality and progression. PMID 19020325.

2011 — HPTN 052 treatment tests linked transmission and clinical outcomes. PMID 21767103.

2015 — START tests immediate treatment against deferred initiation. PMID 26192873.

Research gaps

A necessary antecedent is distinct from infection-alone sufficiency.

Specific host and coinfection mechanisms remain incompletely identified.

Which residual outcomes reflect irreversible injury, coinfection, treatment toxicity or ongoing viral biology?

Phenotype similarity cannot establish etiologic identity.

Selected body access and unexamined linked correction details limit this review.

Study that would resolve the boundary

A stronger necessity-and-sufficiency assessment would require a prospectively specified noncircular syndrome definition and independently verified naturally acquired HIV status, host modifiers, exposure history and longitudinal outcomes. Use ethically delivered target-engaged treatment and adjudicated natural-course/clinical-care observations; do not induce infection or withhold effective therapy. The purpose is causal scope discrimination rather than recreating established treatment harm.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks: all 63 REFERENCES PMIDs verified against PubMed metadata (63/63 resolved to the stated title, first author, journal and year; no retraction or expression-of-concern notices; collective authors such as "INSIGHT START Study Group" render correctly, and reports sharing a parent study carry a shared Study: identifier as v5.3 requires); 11 load-bearing claims spot-checked against the cited abstracts; scoring logic re-derived against references/hsef-framework.md and SKILL.md Steps 2-3, 11 and 12 (six universal caps, primary-subclaim aggregation, independence basis, upper-ladder reachability, confidence band, Momentum/Stability/Divergence artifacts).

Rejected findings (checked, no change): - Headline Θ. Ω is correctly withheld: it requires necessity and sufficiency, and infection is not sufficient for AIDS independently of host factors, duration and treatment; Η would understate the predictive consistency documented by acquisition chronology, randomized suppression, the interruption counter-test and randomized prevention. Scoring the mainstream causal claim high is what the framework's upper-ladder and calibration sections require, not credulity. - Primary-subclaim aggregation on SC3 returns Θ, and both alternatives are reported (weakest-link Η, scope-matched Θ). - Momentum "Mechanistic only" is correct and carries its artifact: the named programmes (START NCT00867048, CHER NCT00102960, HPTN052 NCT00074581, elite-controller phenotyping PMID 38376918) are completed or mechanistic, and none is a running experiment that could cross the next rung. - Divergence "Aligned" states the implied level and the arithmetic (field framing Θ; assessed Θ; gap 0). - Role "primary driver" derived at step 3 with all three conditions addressed, and explicitly distinguished from sole sufficient cause. - Numeric and design claims verified: START primary composite hazard ratio 0.43 with serious AIDS-related events 0.28 and blinded event review (PMID 26192873); SMART hazard ratio 2.6 for opportunistic disease or death, falling to 1.5 after time-updated CD4/RNA adjustment (PMID 17135583); HPTN052 clinical primary composite 0.73, p=0.074, non-significant beside new-onset AIDS events 0.64, p=0.031 (PMID 24602844); CHER 76% mortality reduction in infants (PMID 19020325); immediate ART in tuberculous meningitis with no mortality benefit and more grade 4 adverse events (PMID 21596680); CASCADE non-progression defined as AIDS-free, ART-naive and CD4 at least 500, with most long-term non-progressors later losing that status (PMID 26423816); a documented HIV infection in a CCR5-delta32 homozygote (PMID 18648518). - Non-HIV idiopathic CD4 lymphocytopenia is used to bound phenotype specificity rather than to deny the viral cause, which is the correct treatment of that evidence.

Residual limitations: access depth is unchanged at 3 partial-body and 60 abstract/status examinations, so claims resting on full-text or supplementary detail are verified only to that depth; adjudication.json (the authoring run's decision record) still carries the pre-correction confidence and empty pitfall arrays and was deliberately left as a provenance record.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Mehendale SM, Bollinger RC, Kulkarni SS et al. Rapid disease progression in human immunodeficiency virus type 1-infected seroconverters in India. AIDS research and human retroviruses. 2002. PMID 12487823. DOI: 10.1089/08892220260387913. Access: abstract_metadata. Study: PMID12487823.

2. Ioannidis JP, O'Brien TR, Goedert JJ. Evaluation of guidelines for initiation of highly active antiretroviral therapy in a longitudinal cohort of HIV-infected individuals. AIDS (London, England). 1998. PMID 9875579. DOI: 10.1097/00002030-199818000-00010. Access: abstract_metadata. Study: PMID9875579.

3. Schellens IM, Borghans JA, Jansen CA et al. Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time. PloS one. 2008. PMID 18648514. DOI: 10.1371/journal.pone.0002745. Access: abstract_metadata. Study: PMID18648514.

4. Yeo AE, Matsumoto A, Hisada M et al. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Annals of internal medicine. 2000. PMID 10858179. DOI: 10.7326/0003-4819-132-12-200006200-00006. Access: abstract_metadata. Study: PMID10858179.

5. van Rij RP, Hazenberg MD, van Benthem BH et al. Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution. AIDS research and human retroviruses. 2003. PMID 12803997. DOI: 10.1089/088922203765551737. Access: abstract_metadata. Study: PMID12803997.

6. Rubio Caballero M, Nogués Biau A, Falguera Sacrest M et al. [The prognostic markers of HIV infection progression. A study of the p24 antigen in a cohort of 251 patients]. Anales de medicina interna (Madrid, Spain : 1984). 1999. PMID 10609356. No DOI in the PubMed record. Access: abstract_metadata. Study: SPANISH_251.

7. Rubio Caballero M, Nogués Biau A, Falguera Sacrest M et al. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients]. Anales de medicina interna (Madrid, Spain : 1984). 2000. PMID 11109648. No DOI in the PubMed record. Access: abstract_metadata. Study: SPANISH_251.

8. Gibbons J, Cory JM, Hewlett IK et al. Silent infections with human immunodeficiency virus type 1 are highly unlikely in multitransfused seronegative hemophiliacs. Blood. 1990. PMID 2242420. No DOI in the PubMed record. Access: abstract_metadata. Study: PMID2242420.

9. Hay CR, Ludlam CA, Lowe GD et al. The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison. British journal of haematology. 1998. PMID 9674733. DOI: 10.1046/j.1365-2141.1998.00753.x. Access: abstract_metadata. Study: PMID9674733.

10. Katsarou O, Touloumi G, Antoniou A et al. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients. Haemophilia : the official journal of the World Federation of Hemophilia. 2005. PMID 16011588. DOI: 10.1111/j.1365-2516.2005.01109.x. Access: abstract_metadata. Study: PMID16011588.

11. Schinaia N, Ghirardini AM, Mazzucconi MG et al. Clinical factors associated with progression to AIDS in the Italian cohort of HIV-positive hemophiliacs. G.I.C.C. Gruppo Italiano Coagulopatie Congenite. Thrombosis and haemostasis. 1994. PMID 7974372. No DOI in the PubMed record. Access: abstract_metadata. Study: PMID7974372.

12. Marmor M, Sheppard HW, Donnell D et al. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. Journal of acquired immune deficiency syndromes (1999). 2001. PMID 11511825. DOI: 10.1097/00126334-200108150-00009. Access: abstract_metadata. Study: PMID11511825.

13. Rodés B, Toro C, Paxinos E et al. Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS (London, England). 2004. PMID 15166526. DOI: 10.1097/00002030-200405210-00004. Access: abstract_metadata. Study: PMID15166526.

14. Hendel H, Caillat-Zucman S, Lebuanec H et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. Journal of immunology (Baltimore, Md. : 1950). 1999. PMID 10352317. No DOI in the PubMed record. Access: abstract_metadata. Study: PMID10352317.

15. Kostrikis LG, Neumann AU, Thomson B et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. Journal of virology. 1999. PMID 10559343. DOI: 10.1128/JVI.73.12.10264-10271.1999. Access: abstract_metadata. Study: PMID10559343.

16. Zapata W, Aguilar-Jiménez W, Pineda-Trujillo N et al. Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV in serodiscordant couples from Colombia. AIDS research and human retroviruses. 2013. PMID 24098976. DOI: 10.1089/aid.2012.0299. Access: abstract_metadata. Study: PMID24098976.

17. Yang C, Li M, Limpakarnjanarat K et al. Polymorphisms in the CCR5 coding and noncoding regions among HIV type 1-exposed, persistently seronegative female sex-workers from Thailand. AIDS research and human retroviruses. 2003. PMID 13678468. DOI: 10.1089/088922203322280883. Access: abstract_metadata. Study: PMID13678468.

18. Oh DY, Jessen H, Kücherer C et al. CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual. PloS one. 2008. PMID 18648518. DOI: 10.1371/journal.pone.0002747. Access: abstract_metadata. Study: PMID18648518.

19. Riabov GS, Kazennova EV, Korepanova LB et al. [The HIV-infection outbreak in the town Lys'va (Perm region): homozygote genotype CCR5 delta32/CCR5 delta32 provides the high level of the persistence in the parenteral transmission of the virus]. Voprosy virusologii. 2002. PMID 12271718. No DOI in the PubMed record. Access: abstract_metadata. Study: PMID12271718.

20. Parczewski M, Leszczyszyn-Pynka M, Kaczmarczyk M et al. Sequence variants of chemokine receptor genes and susceptibility to HIV-1 infection. Journal of applied genetics. 2009. PMID 19433914. DOI: 10.1007/BF03195668. Access: abstract_metadata. Study: PMID19433914.

21. Vince N, Bashirova AA, Lied A et al. HLA class I and KIR genes do not protect against HIV type 1 infection in highly exposed uninfected individuals with hemophilia A. The Journal of infectious diseases. 2014. PMID 24719475. DOI: 10.1093/infdis/jiu214. Access: abstract_metadata. Study: PMID24719475.

22. Trecarichi EM, Tumbarello M, de Gaetano Donati K et al. Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. AIDS research and therapy. 2006. PMID 16999868. DOI: 10.1186/1742-6405-3-22. Access: abstract_metadata. Study: PMID16999868.

23. Suresh P, Wanchu A, Sachdeva RK et al. Gene polymorphisms in CCR5, CCR2, CX3CR1, SDF-1 and RANTES in exposed but uninfected partners of HIV-1 infected individuals in North India. Journal of clinical immunology. 2006. PMID 16865553. DOI: 10.1007/s10875-006-9036-0. Access: abstract_metadata. Study: PMID16865553.

24. Baker JV, Neuhaus J, Duprez D et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. Journal of acquired immune deficiency syndromes (1999). 2011. PMID 20930640. DOI: 10.1097/QAI.0b013e3181f7f61a. Access: abstract_metadata. Study: SMART.

25. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. The Journal of infectious diseases. 2008. PMID 18476292. DOI: 10.1086/586713. Access: abstract_metadata. Study: SMART.

26. Finkelstein DM, Williams PL, Molenberghs G et al. Patterns of opportunistic infections in patients with HIV infection. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association. 1996. PMID 8624759. DOI: 10.1097/00042560-199605010-00006. Access: abstract_metadata. Study: PMID8624759.

27. Rabeneck L, Hartigan PM, Huang IW et al. Predicting outcomes in HIV-infected veterans: II. Survival after AIDS. Journal of clinical epidemiology. 1997. PMID 9393380. DOI: 10.1016/s0895-4356(97)00182-0. Access: abstract_metadata. Study: PMID9393380.

28. Teglbjaerg LL, Mathiesen LR, Søeberg B et al. Zidovudine treatment of AIDS and ARC in Denmark 1987. Scandinavian journal of infectious diseases. 1989. PMID 2685984. DOI: 10.3109/00365548909167439. Access: abstract_metadata. Study: PMID2685984.

29. Fowler MG, Qin M, Fiscus SA et al. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. The New England journal of medicine. 2016. PMID 27806243. DOI: 10.1056/NEJMoa1511691. Access: abstract_metadata. Study: NCT01061151+NCT01253538.

30. Severe P, Juste MA, Ambroise A et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. The New England journal of medicine. 2010. PMID 20647201. DOI: 10.1056/NEJMoa0910370. Access: abstract_metadata. Study: NCT00120510.

31. Delta Coordinating Committee, Delta Virology Committee. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. AIDS (London, England). 1999. PMID 10207545. DOI: 10.1097/00002030-199901140-00008. Access: abstract_metadata. Study: PMID10207545.

32. Török ME, Yen NT, Chau TT et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011. PMID 21596680. DOI: 10.1093/cid/cir230. Access: abstract_metadata. Study: PMID21596680.

33. Brady MT, McGrath N, Brouwers P et al. Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). Pediatric AIDS Clinical Trials Group. The Journal of infectious diseases. 1996. PMID 8627060. DOI: 10.1093/infdis/173.5.1097. Access: abstract_metadata. Study: PMID8627060.

34. Fischl MA, Parker CB, Pettinelli C et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. The New England journal of medicine. 1990. PMID 1977079. DOI: 10.1056/NEJM199010113231501. Access: abstract_metadata. Study: PMID1977079.

35. Kumarasamy N, Flanigan TP, Vallabhaneni S et al. A randomised control trial of structured interrupted generic antiretroviral therapy versus continuous therapy in HIV-infected individuals in Southern India. AIDS care. 2007. PMID 17453591. DOI: 10.1080/09540120701213849. Access: abstract_metadata. Study: PMID17453591.

36. Kouamé GM, Boyd A, Moh R et al. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018. PMID 29020361. DOI: 10.1093/cid/cix747. Access: abstract_metadata. Study: TEMPRANO.

37. Kumwenda NI, Hoover DR, Mofenson LM et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. The New England journal of medicine. 2008. PMID 18525035. DOI: 10.1056/NEJMoa0801941. Access: abstract_metadata. Study: NCT00115648.

38. Sutthent R, Chokephaibulkit K, Piyasujabul D et al. Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2002. PMID 12126721. DOI: 10.1016/s1386-6532(01)00258-x. Access: abstract_metadata. Study: PMID12126721.

39. Nagot N, Kankasa C, Tumwine JK et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet (London, England). 2016. PMID 26603917. DOI: 10.1016/S0140-6736(15)00984-8. Access: abstract_metadata. Study: NCT00640263.

40. Holman RC, Gomperts ED, Jason JM et al. Age and human immunodeficiency virus infection in persons with hemophilia in California. American journal of public health. 1990. PMID 2114801. DOI: 10.2105/ajph.80.8.967. Access: abstract_metadata. Study: PMID2114801.

41. Tassie JM, Grabar S, Lancar R et al. Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. Journal of acquired immune deficiency syndromes (1999). 2002. PMID 12048367. DOI: 10.1097/00042560-200205010-00011. Access: abstract_metadata. Study: PMID12048367.

42. Cozzi Lepri A, Sabin CA, Phillips AN et al. The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. The Italian Seroconversion Study. Epidemiology and infection. 1998. PMID 9825787. DOI: 10.1017/s095026889800140x. Access: abstract_metadata. Study: PMID9825787.

43. Phillips AN, Lee CA, Elford J et al. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. Journal of acquired immune deficiency syndromes. 1991. PMID 1679845. No DOI in the PubMed record. Access: abstract_metadata. Study: PMID1679845.

44. Colombe S, Machemba R, Mtenga B et al. Impact of schistosome infection on long-term HIV/AIDS outcomes. PLoS neglected tropical diseases. 2018. PMID 29965987. DOI: 10.1371/journal.pntd.0006613. Access: abstract_metadata. Study: PMID29965987.

45. Daar ES, Kesler KL, Petropoulos CJ et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007. PMID 17683002. DOI: 10.1086/520650. Access: abstract_metadata. Study: PMID17683002.

46. Zonios DI, Falloon J, Bennett JE et al. Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood. 2008. PMID 18456875. DOI: 10.1182/blood-2007-12-127878. Access: abstract_metadata. Study: PMID18456875.

47. Régent A, Autran B, Carcelain G et al. Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients. Medicine. 2014. PMID 24646462. DOI: 10.1097/MD.0000000000000017. Access: abstract_metadata. Study: PMID24646462.

48. Cudrici CD, Boulougoura A, Sheikh V et al. Characterization of autoantibodies, immunophenotype and autoimmune disease in a prospective cohort of patients with idiopathic CD4 lymphocytopenia. Clinical immunology (Orlando, Fla.). 2021. PMID 33422677. DOI: 10.1016/j.clim.2021.108664. Access: abstract_metadata. Study: PMID33422677.

49. Gasca-Capote C, Lian X, Gao C et al. The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers. The Journal of clinical investigation. 2024. PMID 38376918. DOI: 10.1172/JCI174215. Access: abstract_metadata. Study: PMID38376918.

50. Salgado M, Simón A, Sanz-Minguela B et al. An additive effect of protective host genetic factors correlates with HIV nonprogression status. Journal of acquired immune deficiency syndromes (1999). 2011. PMID 21084992. DOI: 10.1097/QAI.0b013e3182036f14. Access: abstract_metadata. Study: PMID21084992.

51. INSIGHT START Study Group, Lundgren JD, Babiker AG et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. The New England journal of medicine. 2015. PMID 26192873. DOI: 10.1056/NEJMoa1506816. Access: full_text_partial. Study: NCT00867048.

52. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J et al. CD4+ count-guided interruption of antiretroviral treatment. The New England journal of medicine. 2006. PMID 17135583. DOI: 10.1056/NEJMoa062360. Access: abstract_metadata. Study: SMART.

53. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. The New England journal of medicine. 2015. PMID 26193126. DOI: 10.1056/NEJMoa1507198. Access: abstract_metadata. Study: TEMPRANO.

54. Fischl MA, Richman DD, Grieco MH et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. The New England journal of medicine. 1987. PMID 3299089. DOI: 10.1056/NEJM198707233170401. Access: abstract_metadata. Study: PMID3299089.

55. Mellors JW, Rinaldo CR, Gupta P et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (New York, N.Y.). 1996. PMID 8638160. DOI: 10.1126/science.272.5265.1167. Access: abstract_metadata. Study: PMID8638160.

56. Grant RM, Lama JR, Anderson PL et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England journal of medicine. 2010. PMID 21091279. DOI: 10.1056/NEJMoa1011205. Access: abstract_metadata. Study: NCT00458393.

57. Baeten JM, Donnell D, Ndase P et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England journal of medicine. 2012. PMID 22784037. DOI: 10.1056/NEJMoa1108524. Access: abstract_metadata. Study: NCT00557245.

58. Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. The New England journal of medicine. 2011. PMID 21767103. DOI: 10.1056/NEJMoa1105243. Access: abstract_metadata. Study: HPTN052.

59. Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. The New England journal of medicine. 1994. PMID 7935654. DOI: 10.1056/NEJM199411033311801. Access: abstract_metadata. Study: PMID7935654.

60. Violari A, Cotton MF, Gibb DM et al. Early antiretroviral therapy and mortality among HIV-infected infants. The New England journal of medicine. 2008. PMID 19020325. DOI: 10.1056/NEJMoa0800971. Access: full_text_partial. Study: NCT00102960.

61. Grinsztejn B, Hosseinipour MC, Ribaudo HJ et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. The Lancet. Infectious diseases. 2014. PMID 24602844. DOI: 10.1016/S1473-3099(13)70692-3. Access: full_text_partial. Study: HPTN052.

62. Mangal TD, UNAIDS Working Group on CD4 Progression and Mortality Amongst HIV Seroconverters including the CASCADE Collaboration in EuroCoord. Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection. AIDS (London, England). 2017. PMID 28301424. DOI: 10.1097/QAD.0000000000001437. Access: abstract_metadata. Study: CASCADE_POOLED.

63. van der Helm JJ, Geskus R, Lodi S et al. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. The lancet. HIV. 2014. PMID 26423816. DOI: 10.1016/S2352-3018(14)70016-5. Access: abstract_metadata. Study: CASCADE_POOLED.

Source-specific evidence cards

[1] Rapid disease progression in human immunodeficiency virus type 1-infected seroconverters in India.

Shows: Documented seroconversion precedes increasing viral load and CD4 decline in 46 untreated Indian participants.

Does not show: Two-year small cohort does not alone isolate HIV from host and setting modifiers.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[2] Evaluation of guidelines for initiation of highly active antiretroviral therapy in a longitudinal cohort of HIV-infected individuals.

Shows: Historical untreated progression differs across candidate ART-initiation criteria.

Does not show: Prediction of historical progression is not a randomized comparison of the recommended thresholds.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[3] Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time.

Shows: Early measured HIV-specific CD8 cytokine responses did not predict AIDS-free survival or CD4 decline.

Does not show: Null immune-marker prediction does not refute HIV causation; the immunologic assay is a proxy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[4] Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study.

Shows: HGV-positive infected hemophiliacs had higher CD4 counts and better AIDS-free survival after adjustment.

Does not show: Coinfection association with uncertain mechanism does not establish a required protective cause.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[5] Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution.

Shows: Early viral RNA and CD4 counts predicted later phenotype evolution; selected receptor percentages did not.

Does not show: Correlated host and viral measurements do not identify an independently necessary receptor mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[6] [The prognostic markers of HIV infection progression. A study of the p24 antigen in a cohort of 251 patients].

Shows: Higher and unstable p24 predicted AIDS or death over 24 months in a 251-patient cohort.

Does not show: A prognostic biomarker is not a selective causal intervention; same cohort as PMID11109648.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[7] [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].

Shows: p24 and CD4 predicted three-year outcomes, with reported discrepancies against viral-load comparisons.

Does not show: Same 251-patient cohort as PMID10609356; discrepancies prevent treating all biomarkers as equivalent.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[8] Silent infections with human immunodeficiency virus type 1 are highly unlikely in multitransfused seronegative hemophiliacs.

Shows: Serially followed seronegative multitransfused hemophiliacs showed little evidence of silent infection.

Does not show: This bounds diagnostic failure in a selected exposed cohort; it is not a general absence-of-disease necessity experiment.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[9] The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison.

Shows: Two higher-purity factor VIII cohorts had similar CD4 decline, survival and AIDS illness rates.

Does not show: Both cohorts were HIV infected and nonrandomized; no seronegative comparator and baseline CD4 differed.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[10] Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.

Shows: AIDS risk fell in the post-HAART hemophilia cohort while non-AIDS mortality rose.

Does not show: Historical periods differ in care, survival and liver disease; AIDS and all-cause mortality remain distinct.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[11] Clinical factors associated with progression to AIDS in the Italian cohort of HIV-positive hemophiliacs. G.I.C.C. Gruppo Italiano Coagulopatie Congenite.

Shows: Italian infected hemophiliacs developed AIDS after estimated seroconversion, with age and treatment-associated heterogeneity.

Does not show: Estimated infection times and nonrandomized factor exposure leave confounding.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[12] Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection.

Shows: CCR5 deletion genotypes were associated with lower acquisition risk in high-risk seronegative cohorts.

Does not show: Genotype associations and exposure reporting do not prove absolute resistance or suffice as AIDS-necessity evidence alone.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[13] Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection.

Shows: Some long-term nonprogressors lost CD4 stability with detectable viremia, while others remained controlled.

Does not show: Selected survivors and small samples do not establish inevitable progression or a universal protective mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[14] New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS.

Shows: HLA alleles associated with opposite AIDS progression patterns among selected extreme progressors.

Does not show: Extreme selection, ancestry and multiple allele tests limit causal attribution and generalization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[15] A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants.

Shows: A host regulatory genotype associated with higher perinatal acquisition in untreated mother-infant pairs.

Does not show: Ethnic frequency and subgroup associations do not establish necessity or individual infection certainty.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[16] Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV in serodiscordant couples from Colombia.

Shows: Selected receptor allele frequencies differed among infected, exposed seronegative and healthy Colombian groups.

Does not show: Small observational comparisons and multiple variants require replication; no homozygous deletion was found.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[17] Polymorphisms in the CCR5 coding and noncoding regions among HIV type 1-exposed, persistently seronegative female sex-workers from Thailand.

Shows: Thai exposed seronegative women did not show significant overall haplogroup differences from comparison groups.

Does not show: Very small groups and a suggested two-person pattern do not validate a protective causal instrument.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[18] CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual.

Shows: Deletion heterozygotes had lower viral setpoints and slower CD4 deterioration, but an infected homozygote progressed rapidly.

Does not show: Host protection is incomplete; rare homozygote infection contradicts an absolute genotype barrier, not HIV causation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[19] [The HIV-infection outbreak in the town Lys'va (Perm region): homozygote genotype CCR5 delta32/CCR5 delta32 provides the high level of the persistence in the parenteral transmission of the virus].

Shows: A deletion genotype was enriched among exposed uninfected people in a documented local outbreak.

Does not show: Small observational exposure contrasts with population controls leave ancestry and exposure-dose confounding.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[20] Sequence variants of chemokine receptor genes and susceptibility to HIV-1 infection.

Shows: CCR5 variants differed between HIV-positive adults and neonatal population controls.

Does not show: Different-age and exposure-unmatched controls cannot establish a clean resistance natural experiment.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[21] HLA class I and KIR genes do not protect against HIV type 1 infection in highly exposed uninfected individuals with hemophilia A.

Shows: Tested HLA and KIR configurations did not explain resistance in exposed uninfected hemophiliacs.

Does not show: Negative selected genetic associations do not refute HIV causation or rule out other protective pathways.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[22] Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals.

Shows: Deletion heterozygosity was more frequent in a small exposed seronegative Italian group.

Does not show: Small selected observational cohorts and self-reported exposure restrict instrument validity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[23] Gene polymorphisms in CCR5, CCR2, CX3CR1, SDF-1 and RANTES in exposed but uninfected partners of HIV-1 infected individuals in North India.

Shows: Tested variants were not significantly associated with resistance in exposed North Indian partners.

Does not show: Small sample and an unexamined linked erratum limit inference; null variants are not proof that host factors never matter.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMIDnot supplied. Subclaims: SC3.

[24] Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.

Shows: Immediate ART improved CD4 counts and reduced D-dimer relative to deferred treatment, with other inflammatory markers null.

Does not show: SMART secondary biomarker report is not independent clinical replication and biomarkers alone do not prove AIDS prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[25] Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Shows: SMART baseline untreated subgroup had more clinical events under the deferral strategy.

Does not show: Secondary subgroup and wide intervals; grouped with SMART, not an independent randomization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[26] Patterns of opportunistic infections in patients with HIV infection.

Shows: Prior opportunistic infections predicted later infections even after CD4 adjustment in two clinical-trial cohorts.

Does not show: Within-infection prognosis is not direct HIV acquisition causality; parent cohorts may overlap other ART reports.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[27] Predicting outcomes in HIV-infected veterans: II. Survival after AIDS.

Shows: Age, CD4, first AIDS condition and function predicted survival among veterans developing AIDS.

Does not show: Secondary clinical-staging analysis is not an independent intervention test.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[28] Zidovudine treatment of AIDS and ARC in Denmark 1987.

Shows: Zidovudine-treated Danish patients showed CD4 and antigen changes and better mortality than historical controls, with toxicity.

Does not show: Historical comparison cannot isolate drug effect from care and selection; no randomized untreated comparator.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[29] Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.

Shows: PROMISE ART reduced early infant infection relative to zidovudine alone, while adverse maternal and neonatal outcomes differed.

Does not show: Active comparators and competing toxicity prevent interpreting HIV-free survival as proof of universal harmlessness or AIDS sufficiency.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[30] Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.

Shows: Randomized earlier ART in Haiti reduced deaths and incident tuberculosis compared with later initiation.

Does not show: A specific baseline CD4 and care setting; treatment benefit does not imply every infected person necessarily progresses.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[31] HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.

Shows: Randomized Delta regimens produced differing RNA suppression; attained RNA nadir predicted subsequent survival.

Does not show: Within-trial mediator association is not randomized viral-load assignment; an extended report shares parent randomization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[32] Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.

Shows: Immediate ART did not improve mortality or AIDS-event/death timing in HIV-associated tuberculous meningitis and increased grade-four harms.

Does not show: A timing contrast in severe CNS infection does not test eliminating HIV versus persistent infection or refute its causal antecedence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[33] Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). Pediatric AIDS Clinical Trials Group.

Shows: Double-blind high- versus low-dose zidovudine in children showed no efficacy or tolerance difference.

Does not show: Two active regimens do not establish efficacy against no treatment or monotonic benefit from greater dosage.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[34] A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

Shows: Lower-dose zidovudine improved survival versus the standard dose and reduced selected toxicities, without changing OI timing.

Does not show: Active-dose comparison separates dose toxicity from virus causation and does not supply independent untreated counterfactual.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[35] A randomised control trial of structured interrupted generic antiretroviral therapy versus continuous therapy in HIV-infected individuals in Southern India.

Shows: A small short-cycle interruption trial maintained CD4 above its primary threshold with few virologic failures and no deaths.

Does not show: Only 35 randomized people and brief follow-up; not the same interruption strategy or endpoint as SMART.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[36] Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.

Shows: High HBV replication predicted mortality despite early ART, without interaction by ART strategy.

Does not show: TEMPRANO secondary cohort; coinfection mortality is not equivalent to HIV-independent AIDS.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[37] Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.

Shows: Extended infant antiretroviral prophylaxis reduced postnatal HIV acquisition relative to the control strategy.

Does not show: Acquisition rather than AIDS is the endpoint; a linked correction is retained and its details were not examined.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID29898374. Subclaims: SC3.

[38] Effect of perinatal short-course zidovudine on the clinical and virological manifestations of HIV-1 subtype E infection in infants.

Shows: Among twelve infected infants, prior prophylaxis exposure associated with more early symptoms and higher viral measurements.

Does not show: Conditioning on breakthrough infection and tiny samples creates selection bias; this does not estimate prophylaxis harm across all randomized infants.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[39] Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.

Shows: Two active infant prophylaxis regimens had similar low acquisition rates, without superiority of one.

Does not show: No placebo/no-prophylaxis arm; a linked correction was not examined and absolute causal prevention cannot be estimated from this comparison alone.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID31232371. Subclaims: SC3.

[40] Age and human immunodeficiency virus infection in persons with hemophilia in California.

Shows: California hemophilia surveillance documented HIV prevalence and age-associated cumulative AIDS after infection.

Does not show: Serologic status was known in only part of the clinic population and no uninfected clinical counterfactual was reported in the examined passage.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[41] Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection.

Shows: Known-date French infection cohorts had longer estimated time to AIDS across increasingly potent treatment eras.

Does not show: Calendar and treatment selection confounding remain; model-estimated incubation is not observed universal lifespan.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[42] The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. The Italian Seroconversion Study.

Shows: Earlier CD4 slope predicted subsequent AIDS beyond latest count in seroconversion cohorts.

Does not show: Prediction of disease trajectory does not itself manipulate the upstream virus.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[43] More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts.

Shows: Older infected hemophiliacs progressed faster after seroconversion, including after CD4 adjustment.

Does not show: Age and care confounding remain; heterogeneity rejects a single inevitable timetable.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[44] Impact of schistosome infection on long-term HIV/AIDS outcomes.

Shows: Schistosome coinfection associated with slower adverse HIV outcomes, opposite the authors' original hypothesis.

Does not show: Observational competing-risk analysis and immune modifiers are not evidence of AIDS without HIV.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[45] Baseline HIV type 1 coreceptor tropism predicts disease progression.

Shows: Baseline viral phenotype predicted CD4 decline and clinical AIDS progression beyond selected covariates.

Does not show: Phenotype is observational; a linked erratum was not examined and no operational assay inference is needed.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMIDnot supplied. Subclaims: SC1.

[46] Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.

Shows: Non-HIV idiopathic CD4 lymphocytopenia caused persistent low counts and opportunistic illnesses, including some AIDS-defining clinical conditions.

Does not show: This refutes equating every AIDS-like clinical condition with HIV; a different syndrome is not direct refutation of HIV-associated AIDS causation. Linked correction is an author-name correction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMIDnot supplied. Subclaims: SC3.

[47] Idiopathic CD4 lymphocytopenia: clinical and immunologic characteristics and follow-up of 40 patients.

Shows: A French ICL cohort showed heterogeneous immune deficiencies, opportunistic disease and deaths without HIV.

Does not show: The generic low-CD4/OI phenotype has other causes; necessity must be evaluated for the HIV-associated syndrome rather than every immune-deficiency phenotype.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[48] Characterization of autoantibodies, immunophenotype and autoimmune disease in a prospective cohort of patients with idiopathic CD4 lymphocytopenia.

Shows: Prospective ICL referral patients often had autoimmune features and altered immune-cell distributions.

Does not show: Referral selection and unclear initiating mechanism prevent proving a competing universal cause of AIDS.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[49] The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.

Shows: Persistent and transient elite controllers differed in observed reservoir landscape before control loss.

Does not show: Selected infected controllers show modification of course; reservoir comparisons alone do not prove a sufficient protective mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[50] An additive effect of protective host genetic factors correlates with HIV nonprogression status.

Shows: Protective host alleles collectively associated with nonprogression, with prominent HLA effects.

Does not show: Small selected genetic combinations and additive associations do not establish absolute protection or independence from infection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[51] Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Shows: START immediate treatment reduced the primary clinical composite and serious AIDS events with improved CD4 trajectory and viral suppression.

Does not show: Open-label strategy but blinded event review; interim stopping, residual events and nonsignificant all-cause mortality are retained. It does not prove infection-alone sufficiency.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:METHODS:paragraph4, 0:METHODS:paragraph5, 0:METHODS:paragraph8, 1:RESULTS:paragraph4, 1:RESULTS:paragraph5, 1:RESULTS:paragraph6, 1:RESULTS:paragraph8. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[52] CD4+ count-guided interruption of antiretroviral treatment.

Shows: SMART CD4-guided episodic ART increased opportunistic disease/death versus continuous suppression; rising RNA and falling CD4 aligned with harm.

Does not show: Specific interruption strategy and previously treated population; mediator adjustment is not perfect causal mediation and toxicity/coinfections still matter.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[53] A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

Shows: TEMPRANO early ART and tuberculosis preventive treatment independently reduced severe clinical illness or death.

Does not show: Combined clinical composite and setting-specific coinfection prevention; ART and IPT are separate interventions, not proof that all mortality is HIV alone.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[54] The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Shows: Double-blind AZT versus placebo reduced deaths and opportunistic infections over short follow-up with improved function.

Does not show: Selected advanced disease, early termination and drug toxicity limit magnitude and long-term inference; one drug alone does not settle mechanism specificity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[55] Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Shows: Baseline plasma RNA predicted AIDS and death over long follow-up in 180 infected men beyond CD4 prognostic value.

Does not show: Primary cohort despite a Comment indexing tag; observation alone does not establish causation and a linked erratum was not examined.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMIDnot supplied. Subclaims: SC1, SC3.

[56] Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Shows: iPrEx prophylaxis reduced new HIV acquisition versus placebo; measured exposure correlated with protection.

Does not show: Acquisition not AIDS is the randomized endpoint; postrandomization measured exposure association is not independently randomized adherence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[57] Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Shows: Partners PrEP active regimens reduced HIV acquisition versus placebo in serodiscordant couples.

Does not show: The pathway endpoint is infection incidence, not ultimate AIDS necessity or sufficiency; adherence and context matter.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[58] Prevention of HIV-1 infection with early antiretroviral therapy.

Shows: HPTN052 early treatment reduced linked partner acquisition and clinical events.

Does not show: Transmission and clinical follow-up share the same randomization as PMID24602844 and cannot be counted as separate causal lines.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[59] Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Shows: Randomized maternal/infant zidovudine reduced infant acquisition versus placebo.

Does not show: An acquisition-prevention link complements progression trials but alone does not prove downstream AIDS inevitability or drug harmlessness.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[60] Early antiretroviral therapy and mortality among HIV-infected infants.

Shows: CHER earlier infant ART reduced mortality and serious clinical progression with improved CD4 percentages.

Does not show: Infant baseline eligibility, limited early follow-up and reassessment after stopping restrict extrapolation; no infection-alone sufficiency proof.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph4, 1:Results:paragraph6, 1:Results:paragraph7. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[61] Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Shows: HPTN052 follow-up reduced first AIDS events, while the primary clinical composite and mortality comparisons were not significant.

Does not show: Same parent trial as PMID21767103; significant secondary outcomes must not be substituted for a positive primary composite.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Results:paragraph1, 2:Results:paragraph2, 2:Results:paragraph4. No complete-paper or supplement audit claimed. ErratumIn: PMIDnot supplied. Subclaims: SC2, SC3.

[62] Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection.

Shows: Pooled individual seroconverter trajectories showed CD4 deterioration and mortality varying by age and region.

Does not show: Primary participant-data analysis shares contributing cohorts; modeled untreated survival and informative ART initiation are limitations.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[63] Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study.

Shows: Most selected long-term nonprogressors later lost status, with lower CD4 or higher RNA predicting loss.

Does not show: Nonprogression requires untreated status and CD4 at least 500 as well as absence of AIDS; its percentages are not simply AIDS-free survival probabilities. CASCADE overlaps other cohort analyses.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• hiv-aids.review.md
• hiv-aids.scorecard.json
• reader-summary.json
• research-timeline.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 63 · load-bearing claims: 67 · verified: 67 · unverified: 0 · contradicted: 0 · schema 5.3